Where is Spirea located?

Spirea is headquartered in Harrogate, United Kingdom.

Who is the current CEO of Spirea?

Myriam Ouberai of Spirea. They have also founded 1 company.

Which legal entities is Spirea associated with?

Spirea is associated with SPIREA LIMITED.

How many employees does Spirea have?

As of Jun 30, 2026, the latest employee count at Spirea is 8.

Is Spirea a funded company?

Spirea is a funded company, having raised a total of $2.93M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of Spirea?

Spirea's latest funding was a $***** Seed round on Jun 14, 2022, with participation from 7 investors. Its primary sector is Oncology. In United Kingdom, the Oncology sector has seen $511M in funding in 2026 to date.

Where does Spirea rank among its competitors?

Spirea ranks 51st amongst 125 active competitors, of which 50 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Tubulis Technologies, which secured $401M in Oct, 2025.

Who are the top competitors of Spirea?

Spirea's top competitors include STAR Therapeutics, Adagene and TriSalus Life Sciences. Among them, Tubulis Technologies secured the most recent funding round in October, 2025.

Spirea - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

SPIREA is a developer of therapeutic solutions for cancer treatments. It has developed antibody-drug conjugate therapeutics to revolutionize cancer treatment and improve the lives of patients. It combines cytotoxic drug payload with the targeting ability of an antibody that is targeted to kill cancer cells.

Website: spirea.co.uk
Email ID: *****@spirea.co.uk

Key Metrics

Founded Year

2016

Location

Harrogate, United Kingdom

Stage

Seed

Total Funding

$2.93M in 5 rounds

Latest Funding Round

Seed, Jun 14, 2022, $*****

Investors

University of Cambridge & 13 more

Ranked

51^st among 125 active competitors

Employee Count

8 as on Jun 30, 2026

Similar Companies

STAR Therapeutics & 149 more

View Spirea's full profile

Spirea is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SPIREA LIMITED CIN: 9817891 , Germany, Active	Aug 10, 1995	-	2 (As on Oct 31, 2021)

Spirea has raised a total funding of $2.93M over 5 rounds. Its latest funding round was a Seed round on Jun 14, 2022 for $*****. 7 investors participated in its latest round. Spirea has 12 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Spirea:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 14, 2022	4791747	Seed	2925327	2885696	5294136	5111834
Dec 07, 2020	4589858	Seed	1500364	8714706	1981602	6138981
Jul 13, 2020	5385249	Seed	4574914	9514432	Start Codon & 1 more	4505657

Access funding benchmarks and valuations. Sign up today!

View details of Spirea's funding rounds and investors

The founders of Spirea is Myriam Ouberai. Myriam Ouberai is the CEO of Spirea.

Here are the details of Spirea's key team members:

Myriam Ouberai: Founder & CEO of Spirea.
Contact Info: 1 email address

View details of Spirea's Founder profiles and Board Members

Spirea's employee count trend

Spirea has 8 employees as of Jun 26. Here is Spirea's employee count trend over the years:

Uncover Spirea's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Spirea include STAR Therapeutics, Adagene and TriSalus Life Sciences. Here is the list of Top 10 competitors of Spirea, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	STAR Therapeutics 2018, San Francisco (United States), Series D	Developer of antibody therapies for multiple diseases	$215M	Sanofi Ventures, Sofinnova Investments & 18 others	67/100
2nd	Adagene 2012, Suzhou (China), Public	Developer of immunotherapy for the treatment of cancer	$155M	F-Prime Capital, Eight Roads Ventures & 12 others	66/100
3rd	TriSalus Life Sciences 2009, Westminster (United States), Public	Developer of drug delivery devices to treat cancers	$83.4M	Partisan Management Group, High Country Ventures ... & 7 others	66/100
4th	Myricx Bio 2019, London (United Kingdom), Acquired	Developer of antibody drug conjugates for the treatment of cancer	$121M	Novo Holdings, Abingworth & 13 others	65/100
5th	Tagworks Pharmaceuticals 2011, Nijmegen (Netherlands), Series A	Developer of antibody-drug-conjugates for cancer treatment	$65M	Gilde Healthcare, Ysios Capital & 7 others	63/100
6th	Innovent Bio 2011, Suzhou (China), Public	Developer of antibody therapeutics for multiple diseases	$535M	Eight Roads Ventures, Lilly Asia Ventures ... & 24 others	62/100
7th	Tubulis Technologies 2015, Munich (Germany), Acquired	Developer of antibody-drug conjugates for the treatment of cancer	$615M	Nextech Invest, Life Sciences Partners & 27 others	62/100
8th	Delcath 1987, New York City (United States), Public	Speciality Pharmaceutical and medical device company focused on oncology	-	BVF Partners, Vivo Capital & 8 others	61/100
9th	Dren Bio 2019, San Carlos (United States), Series B	Developer of therapeutic antibodies for the treatment of cancer, autoimmune, and other serious diseases	$156M	Aisling Capital, Taiho Ventures & 13 others	61/100
10th	Vigil 2020, Cambridge (United States), Acquired	Developer of therapeutic solutions for treating multiple neurodegenerative diseases	$140M	Atlas Venture, Northpond Ventures & 14 others	61/100
51st	Spirea 2016, Harrogate (United Kingdom), Seed	Developer of therapeutic solutions for cancer treatments	$2.93M	University of Cambridge, ACF Investors & 12 others	39/100